Our data support the continued development of bromodomain inhibitors and further investigation of their utility in combinatorial therapeutic strategies for KRAS-mutant CRC, to maximize response to targeted agents and suppress mechanisms of intrinsic and acquired resistance. Here, KRAS is linked to colorectal carcinoma.